Julie A. Stone
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Alzheimer's disease research and treatments, HIV/AIDS drug development and treatment, Computational Drug Discovery Methods, Cholinesterase and Neurodegenerative Diseases, Statistical Methods in Clinical Trials
Most-Cited Works
- → The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients(2016)410 cited
- → Evaluation of dosing strategy for pembrolizumab for oncology indications(2017)247 cited
- → Single- and Multiple-Dose Pharmacokinetics of Caspofungin in Healthy Men(2002)246 cited
- → Pharmacokinetics, Safety, and Tolerability of Caspofungin in Children and Adolescents(2005)239 cited
- → Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance(2018)207 cited
- → Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)–A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer’s Disease(2016)161 cited